Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4WJX3)

Drug Name

3-methoxy-N-(4-methylthiazol-2-yl)benzamide Drug Info

Synonyms

CHEMBL211740; 477516-34-0; 3-methoxy-N-(4-methyl-1,3-thiazol-2-yl)benzamide; SMR000155061; AC1MAGB1; 3-methoxy-N-(4-methylthiazol-2-yl)benzamide; Oprea1_281072; Oprea1_273858; MLS000569675; CTK4J0236; cid_2679292; DTXSID80369021; MolPort-000-631-036; CHEBI:114888; HMS2341M09; ZINC3562014; BDBM50186332; AKOS001313290; MCULE-7375167923; KB-288021; BENZAMIDE, 3-METHOXY-N-(4-METHYL-2-THIAZOLYL)-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 2679292
ChEBI ID: CHEBI:114888
CAS Number: CAS 477516-34-0
TTD Drug ID: DM4WJX3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Discontinued Drug(s)

Investigative Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting LOX-5 messenger RNA (ALOX5 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TEBUFELONE	DMMUE8P	Pain	MG30-MG3Z	Discontinued in Phase 2	[3]
ZD-2138	DMVFCX7	Asthma	CA23	Discontinued in Phase 2	[4]
BW A4C	DMNUMDG	Arthritis	FA20	Terminated	[5]
KAEMPFEROL	DMHEMUB	Discovery agent	N.A.	Investigative	[6]
2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl	DMWNJ84	Discovery agent	N.A.	Investigative	[7]
METHYLHONOKIOL	DM9YE6K	Discovery agent	N.A.	Investigative	[7]
HONOKIOL	DMJWT3X	Discovery agent	N.A.	Investigative	[7]
PUUPEHEDIONE	DMF28IU	Discovery agent	N.A.	Investigative	[8]
PUUPEHENONE	DMF3BCK	Discovery agent	N.A.	Investigative	[8]
Isojaspic acid	DMHTBDN	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Metabotropic glutamate receptor 5 (mGluR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AFQ056	DMMHSLC	Fragile X syndrome	LD55	Phase 2/3	[9]
ADX-48621	DM6GTMD	Parkinson disease	8A00.0	Phase 2/3	[10]
RG-7090	DMX8JYN	Fragile X syndrome	LD55	Phase 2	[11]
STX-107	DMLNKX7	Autism spectrum disorder	6A02	Phase 2	[12]
ADX10059	DMGVKHQ	Anxiety disorder	6B00-6B0Z	Phase 2	[13]
McN3377	DMTCADJ	Fragile X syndrome	LD55	Phase 1/2	[14]
MK-3328	DMW2O5D	Alzheimer disease	8A20	Phase 1	[15]
[3H]fenobam	DMBOXA1	Allodynia	MB40.1	Phase 1	[16]
RG7342	DMIW5NG	Schizophrenia	6A20	Phase 1	[17]
BMS-984923	DMFNDUL	Alzheimer disease	8A20	Phase 1	[18]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
LOX-5 messenger RNA (ALOX5 mRNA)	TTSJ6Q4	LOX5_HUMAN	Inhibitor	[2]
Metabotropic glutamate receptor 5 (mGluR5)	TTHS256	GRM5_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5.
2	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
3	New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflam... J Med Chem. 1998 Aug 27;41(18):3515-29.
4	Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines. Bioorg Med Chem. 2010 Jun 1;18(11):3910-24.
5	Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid. J Med Chem. 2008 Sep 11;51(17):5449-53.
6	Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62.
7	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
8	Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63.
9	Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41.
10	Pipeline of Addex Pharma. Addex Pharma. 2009.
11	The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250.
12	Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
13	A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9.
14	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
16	Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21.
17	Clinical pipeline report, company report or official report of Roche.
18	Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes. Cell Rep. 2017 Jul 5;20(1):76-88.